SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
[January 07, 2020]

RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference


SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., its President and CEO, will present a corporate update and company overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 11:30 a.m. Pacific Time in San Francisco.

A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.comevents-and-presentations. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.



About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company rapidly develops highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has a diversified portfolio with near-term clinical milestones expected in 2020. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4, for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including general control nonderepressible 2 (GCN2) and hematopoietic progenitor kinase 1 (HPK1), that are in the discovery stage of development.

Media Contact:
Angela Bitting
media@rapt.com
(925) 202-6211


Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

Primary Logo


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA
Ph: +1-203-852-6800, 800-243-6002

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2020 Technology Marketing Corporation. All rights reserved | Privacy Policy